Business & Finance
NANOBIOTIX collects Q3 2019 revenues of EUR11,000
28 October 2019 -

Nanomedicine company NANOBIOTIX (Euronext:NANO) (ISIN:FR0011341205) on Friday announced revenues of EUR11,000 for the third quarter of 2019.

This marks a decline when compared with revenues of EUR32,000 for the third quarter of 2018.

The company generated revenues of EUR48,000 for the nine months ended 30 September 2019, down over revenues EUR95,000 for the nine months ended 30 September 2018.

Most of the revenues generated by the company during this period result from the recharge of costs related to its license and collaboration agreement with PharmaEngine.

As of 30 September 2019, the company's cash availability and financial investment was EUR47.3m.

Login
Username:

Password: